Altimmune to Participate at Two Upcoming Investor Conferences
Rhea-AI Summary
Altimmune (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on liver and cardiometabolic diseases, has announced its participation in two upcoming investor conferences. Management will attend the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, with a fireside chat at 10:00 AM ET, and the Jefferies Global Healthcare Conference on June 4, 2025, with a fireside chat at 9:55 AM ET. Both events will take place in New York, and webcasts will be available on Altimmune's website. The company will also be available for one-on-one meetings during these conferences.
Positive
- None.
Negative
- None.
News Market Reaction – ALT
In the trading session that priced this news, ALT declined 1.04%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:
- H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, NY)
Tuesday, May 20, 2025
Fireside Chat at 10:00 a.m. Eastern Time
- Jefferies Global Healthcare Conference (New York, NY)
Wednesday, June 4, 2025
Fireside Chat at 9:55 a.m. Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Phone: 619-849-5383
Jake.robison@inizioevoke.com
This press release was published by a CLEAR® Verified individual.
